Lunresertib

Lunresertib is an investigational new drug that is being evaluated for the treatment of cancer. It is an oral small molecule inhibitor of PKMYT1, developed by Repare Therapeutics.[1] This drug targets cell cycle regulation in tumors with specific genetic alterations, including CCNE1 amplifications or FBXW7 and PPP2R1A loss of function mutations. It is currently in phase 1/2 clinical trials, both as monotherapy or in combination with camonsertib, an ATR inhibitor.[2]

## References

1. ↑ "Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306". Journal of Medicinal Chemistry 65 (15): 10251–10284. August 2022. doi:10.1021/acs.jmedchem.2c00552. PMID 35880755.
2. ↑ "New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives". Journal of Medicinal Chemistry 67 (14): 11488–11521. July 2024. doi:10.1021/acs.jmedchem.4c00113. PMID 38955347.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Lunresertib. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Lunresertib&oldid=4036189"